These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25627694)

  • 1. Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease.
    Berthier A; Payá M; García-Cabrero AM; Ballester MI; Heredia M; Serratosa JM; Sánchez MP; Sanz P
    Mol Neurobiol; 2016 Mar; 53(2):1296-1309. PubMed ID: 25627694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulators of Neuroinflammation Have a Beneficial Effect in a Lafora Disease Mouse Model.
    Mollá B; Heredia M; Sanz P
    Mol Neurobiol; 2021 Jun; 58(6):2508-2522. PubMed ID: 33447969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease.
    Sánchez-Elexpuru G; Serratosa JM; Sanz P; Sánchez MP
    Neuroreport; 2017 Mar; 28(5):268-271. PubMed ID: 28181916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trehalose Ameliorates Seizure Susceptibility in Lafora Disease Mouse Models by Suppressing Neuroinflammation and Endoplasmic Reticulum Stress.
    Sinha P; Verma B; Ganesh S
    Mol Neurobiol; 2021 Mar; 58(3):1088-1101. PubMed ID: 33094475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models.
    López-González I; Viana R; Sanz P; Ferrer I
    Mol Neurobiol; 2017 Jul; 54(5):3119-3130. PubMed ID: 27041370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion.
    Chambers JK; Thongtharb A; Shiga T; Azakami D; Saito M; Sato M; Morozumi M; Nakayama H; Uchida K
    Vet Pathol; 2018 Jul; 55(4):543-551. PubMed ID: 29444631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
    Zeng L; Wang Y; Baba O; Zheng P; Liu Y; Liu Y
    FEBS J; 2012 Jul; 279(14):2467-78. PubMed ID: 22578008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Astrocytes and neurons produce distinct types of polyglucosan bodies in Lafora disease.
    Augé E; Pelegrí C; Manich G; Cabezón I; Guinovart JJ; Duran J; Vilaplana J
    Glia; 2018 Oct; 66(10):2094-2107. PubMed ID: 30152044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic Dissociation: Robust Lafora Body Accumulation in Malin KO Mice Without Observable Changes in Home-Cage Behavior.
    Krishnan V; Wu J; Mazumder AG; Kamen JL; Schirmer C; Adhyapak N; Bass JS; Lee SC; Maheshwari A; Molinaro G; Gibson JR; Huber KM; Minassian BA
    J Comp Neurol; 2024 Jul; 532(7):e25660. PubMed ID: 39039998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laforin and malin deletions in mice produce similar neurologic impairments.
    García-Cabrero AM; Marinas A; Guerrero R; de Córdoba SR; Serratosa JM; Sánchez MP
    J Neuropathol Exp Neurol; 2012 May; 71(5):413-21. PubMed ID: 22487859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Modulation of Glutamatergic and Neuroinflammatory Pathways in a Lafora Disease Mouse Model.
    Mollá B; Heredia M; Campos Á; Sanz P
    Mol Neurobiol; 2022 Oct; 59(10):6018-6032. PubMed ID: 35835895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy.
    Criado O; Aguado C; Gayarre J; Duran-Trio L; Garcia-Cabrero AM; Vernia S; San Millán B; Heredia M; Romá-Mateo C; Mouron S; Juana-López L; Domínguez M; Navarro C; Serratosa JM; Sanchez M; Sanz P; Bovolenta P; Knecht E; Rodriguez de Cordoba S
    Hum Mol Genet; 2012 Apr; 21(7):1521-33. PubMed ID: 22186026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyglucosan body structure in Lafora disease.
    Brewer MK; Putaux JL; Rondon A; Uittenbogaard A; Sullivan MA; Gentry MS
    Carbohydr Polym; 2020 Jul; 240():116260. PubMed ID: 32475552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysfunctions in endosomal-lysosomal and autophagy pathways underlie neuropathology in a mouse model for Lafora disease.
    Puri R; Suzuki T; Yamakawa K; Ganesh S
    Hum Mol Genet; 2012 Jan; 21(1):175-84. PubMed ID: 21965301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.
    Wang Y; Ma K; Wang P; Baba O; Zhang H; Parent JM; Zheng P; Liu Y; Minassian BA; Liu Y
    Mol Neurobiol; 2013 Aug; 48(1):49-61. PubMed ID: 23546741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of leptin signaling reduces polyglucosan inclusions and seizure susceptibility in a mouse model for Lafora disease.
    Rai A; Mishra R; Ganesh S
    Hum Mol Genet; 2017 Dec; 26(24):4778-4785. PubMed ID: 28973665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
    Ganesh S; Delgado-Escueta AV; Sakamoto T; Avila MR; Machado-Salas J; Hoshii Y; Akagi T; Gomi H; Suzuki T; Amano K; Agarwala KL; Hasegawa Y; Bai DS; Ishihara T; Hashikawa T; Itohara S; Cornford EM; Niki H; Yamakawa K
    Hum Mol Genet; 2002 May; 11(11):1251-62. PubMed ID: 12019206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epm2a
    Burgos DF; Sciaccaluga M; Worby CA; Zafra-Puerta L; Iglesias-Cabeza N; Sánchez-Martín G; Prontera P; Costa C; Serratosa JM; Sánchez MP
    Neurobiol Dis; 2023 Jun; 181():106119. PubMed ID: 37059210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ontogeny of Lafora bodies and neurocytoskeleton changes in Laforin-deficient mice.
    Machado-Salas J; Avila-Costa MR; Guevara P; Guevara J; Durón RM; Bai D; Tanaka M; Yamakawa K; Delgado-Escueta AV
    Exp Neurol; 2012 Jul; 236(1):131-40. PubMed ID: 22542948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease.
    Valles-Ortega J; Duran J; Garcia-Rocha M; Bosch C; Saez I; Pujadas L; Serafin A; Cañas X; Soriano E; Delgado-García JM; Gruart A; Guinovart JJ
    EMBO Mol Med; 2011 Nov; 3(11):667-81. PubMed ID: 21882344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.